Phase III COAST-X study of Taltz in nonradiographic axial spondyloarthritis meets key endpoints April 23, 2019
Shanghai Synergy Pharmaceutical Sciences, Zhejiang Huahai Pharmaceutical patent JAK inhibitors April 17, 2019
Gilead Sciences and Galapagos present updated results for phase III studies of filgotinib March 29, 2019
Cimzia becomes the first and only FDA-approved treatment for nonradiographic axial spondyloarthritis March 29, 2019
RSS